Home › Diffuse Large B-Cell Lymphoma › Nevada
Diffuse Large B-Cell Lymphoma clinical trials in Nevada
3 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Nevada.
Cities in Nevada
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Comprehensive Cancer Centers of Nevada, Las Vegas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Comprehensive Cancer Centers of Nevada ( Site 0168), Las Vegas
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05139017A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- OptumCare Cancer Care ( Site 0121), Las Vegas
- Comprehensive Cancer Centers of Nevada ( Site 0113), Las Vegas
- Cancer Care Specialists ( Site 9582), Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.